Tumors, such as acute lymphocytic leukemia, cancer of the tongue, and cancer of the penis, are becoming more common in the HAART era compared with the pre-HAART era.
Women with a mental disorder, specifically characteristics of antisocial personality disorder and borderline personality disorder, are more sexually active than their male counterparts.
The single tablet regimen is a combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
Virological response, efficacy, noninferiority, and tolerability were tested for bictegravir, emtricitabine, and tenofovir alafenamide vs dolutegravir, abacavir, and lamivudine.
Single measures of viral load can overestimate how many individuals with HIV infection have viral suppression.
HIV, hepatitis B, and hepatitis C infections are more prevalent among patients with severe mental illness than in the general population.
In addition to prevention measures, switching off the ARTs associated with bone loss and administering intravenous bisphosphonate, a bone resorption inhibitor, can be an effective strategy for preventing bone loss seen in HIV-infected individuals.
Point-of-Care Tests for HIV and T pallidum Infections: Utility of Smartphone-Based Electronic ReaderSeptember 08, 2017
A smartphone-based electronic reader with dual point of care tests were evaluated in the detection of antibodies to T pallidum and HIV.
Rapid HIV testing offered to patients in addition to a clinician consultation increases the testing rate in the emergency department.
Women achieving HIV viral suppression in pregnancy can experience viral load rebound predelivery.
The FDA has approved an expanded indication for Epclusa to include the use of this once-daily single tablet regimen in patients co-infected with chronic hepatitis C virus and HIV.
Three HIV experts provide their insights into aging-related challenges and complications faced by people living with HIV.
HIV infection may not contribute to incidence of invasive cervical cancer.
The FDA has granted Priority Review to the New Drug Application for Gilead's investigational single-tablet regimen in the treatment of HIV-1 infection.
The microbiome of the area on the penis located under the foreskin in uncircumcised straight men has been linked to increased risk for contracting HIV.
Patients with HIV undergoing antiretroviral therapy saw significant decreases in bone mineral density.
Femoral neck bone mineral density declines twice as fast in HIV-infected women vs HIV-infected men.
Providers at Walgreens Healthcare Clinics in 17 new locations will be able to prescribe PrEP for HIV prevention.
The CDC systematic review follows a trend of clinicians offering more frequent HIV screening to gay, bisexual, and other men who have sex with men, but the evidence is insufficient to warrant a change to the current recommendations.
The FDA has approved labeling changes for Genvoya to include long-term efficacy, safety, resistance data and drug interactions.
The WHO has alerted countries to take action against the growing threat of HIV drug resistance.
For patients with advanced HIV who are initiating antiretroviral therapy, enhanced prophylaxis is associated with reduced rates of death.
Point-of-care testing of HIV-exposed infants at birth yielded results comparable to the standard of care laboratory-based testing and reduced time to result and time to antiretroviral therapy initiation.
One-week amphotericin plus flucytosine was found to have comparable efficacy and safety profiles as the standard of care, 2-weeks amphotericin-based therapy, for treatment of HIV-associated cryptococcal meningitis in African patients.
In order to assess and manage milder forms of HIV-associated neurocognitive disorders, effective cognitive screening instruments are needed.
New findings announced from a supplemental analysis of Mytesi (crofelemer) in patients with HIV-related diarrhea.
A child who was diagnosed with HIV at 1 month and received early treatment has suppressed the virus without anti-HIV therapy for 8.5 years.
New WHO guidelines address the issue of how to manage pretreatment human immunodeficiency virus drug resistance (HIVDR) in countries where the prevalence of HIVDR is 10% or higher.
The combination of long-acting intramuscular cabotegravir plus rilpivirine was demonstrated to be as effective as 3-drug daily oral ART for maintaining viral suppression of HIV-1 for up to 96 weeks in the LATTE-2 phase 2b study.
Gilead announced results from 2 Phase 3 studies for the investigational fixed-dose HIV regimen with bictegravir and emtricitabine for the treatment of treatment-naive adults with HIV.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- HCC Risk After HCV Direct-Acting Antiviral Treatment
- Influenza Vaccine's Effectiveness Following Repeated Vaccination
- FDA Announces Orphan Drug Designation for HDV Drug
- New Single-Assay Test for Vaginitis Accurate as Traditional Tests
- Dexamethasone Reduces Need for Antibiotics in Adults With Sore Throat
- Bezlotoxumab Reduces 30-Day Hospital Readmissions for C difficile Infection
- FDA: Vabomere Approved for Complicated UTI Following Priority Review
- HCC Risk After HCV Direct-Acting Antiviral Treatment
- New CDC Guidelines for SSI Prevention Leave Unanswered Questions
- Clinic Visits, Costs Decreased by Rotavirus Vaccination in US Children
- Risk for Secondary Tumors After Kaposi Sarcoma Has Changed in the HAART Era
- FDA Approval: Single-Dose Oral Therapy for Bacterial Vaginosis
- HIV Risk Behaviors More Prominent in Women With Mental Disorders
- Influenza Vaccine in Elderly Adults: Is High-Dose Better Than Standard-Dose?
- Once-Daily Single-Tablet HIV Treatment Safe, Effective in Children